Who we are
Board of Recommendation
How to Become a Member
Members’ Activities Calendar
What we do
Policy and Advocacy
Exchange the world
Introduction to IFMSA Exchanges
List of Participating Countries
Research Projects Database
Medical Students International
You are here:
Clinical, cytological, cytometric, karyotypic and molecular biology of patients with hematological malignancies
Spain (IFMSA-SPAIN)-University of Santiago de Compostela, Santiago de Compostela
Hematology Department and Lymphoma Research Group of the Health Research Institute
Dr. Jose; Luis Bello Lopez
Dra. Natalia Alonso Vence
English, Spanish, French, Arab, Italian
Type of Research Project
- Basic science
What is the background of the project?
Hematologic malignancies are a heterogeneous group of malignancies that affecting the blood, bone marrow and lymph nodes. Malignant neoplasms include: -Leukemias: acute lymphoid leukemia, acute lymphoblastic leukemia, precursor acute lymphoblastic leukemia B cells (chronic lymphocytic leukemia), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), Tricho-leukemia, - Lymphoma: Hodgkin's disease (four subtypes) Non-Hodgkin lymphoma (many subtypes) - Multiple Myeloma For the diagnosis and study of a haematological malignancy is needed from a complete blood count and blood smear (essential), tests to characterize the malignant cells by studying their morphology using microscopy. It is also necessary to perform biopsies of lymph node or bone marrow as the analysis of these diseases. All samples must be examined microscopically to determine the nature of malignancy. For an accurate diagnosis requires cytogenetic studies or immunophenotyping (lymphoma, myeloma, CLL) malignant cells. The treatment of these neoplasms is varied depending on the diagnosis. Can range from "watchful waiting" (eg, in the LLC) or symptomatic treatment (eg blood transfusions) to forms that require more aggressive treatment such as treatment with high dose chemotherapy, radiotherapy, immunotherapy and - in some cases - treatments such as autologous or allogeneic transplants.
What is the aim of the project?
To familiarize the students with cytological, cytometric, karyotypic and molecular techniques applied to characterize hematological malignancies.
What techniques and methods are used?
Cytology, flow cytometry, karyotype and molecular techniques.
What is the role of the student?
- If the project includes “lab work”
- the student will take active part in the practical aspect of the project
- If the project is clinical
- the student will be allowed to work with patients
- The tasks will be done under supervision
What are the tasks expected to be accomplished by the student?
Cytological, cytometric, karyotypic and molecular techniques applied to characterize hematological malignancies. The students will participate in regular management task at the laboratory techniques and will be in contact with diagnostic and treatment reality on patients with hematological neoplasms. Depending on the previous knowledges of the student and in their interest for the topic, he/she will be able to colaborate in the daily practise of the cualified profesionals.
Will there be any theoretical teaching provided (preliminary readings, lectures, courses, seminars etc)
Yes, there will be seminars
What is expected from the student at the end of the research exchange? What will be the general outcome of the student?
- The student will prepare a scientific report
What skills are required of the student? Is there any special knowledge or a certain level of studies needed?
Are there any legal limitations in the student’s involvement
Type of students accepted
This project accepts: - Medical students - Graduated students (less than 6 months) - Pre-Medical students from the American-British system
- Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Bustos A; Álvarez R; Aramburo PM; Carabantes F; Díaz N; Florián J; Lázaro M; de Segovia JM; Gasquet JA; Alegre A; RADAR Study Group. Curr Med Res Opin. 2012 Jan; 28(1):57-67. Epub 2011 Nov 23.
- Bortezomib; melphalan; and prednisone versus bortezomib; thalidomide; and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Mateos MV; Oriol A; Martínez- López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF. Lancet Oncol. 2010 Oct;11(10):934-41. Epub 2010 Aug 23.
- Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Lahuerta JJ; Mateos MV; Martínez-López J; Grande C; de la Rubia J; Rosiñol L; Sureda A; García-Laraña J; Díaz-Mediavilla J; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Oriol A; Escoda L; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF; Grupo Español de MM and Programa para el Estudio de la Terapéutica en Hemopatía Maligna Cooperative Study Groups. Haematologica. 2010 Nov;95(11):1913-20. Epub 2010 Jul 27.
- Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García- Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ; Spanish Myeloma Group/PETHEMA. Biol Blood Marrow Transplant. 2007 Dec;13(12):1448-54.
- Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor; whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Gutiérrez NC; Castellanos MV; Martín ML; Mateos MV; Hernández JM; Fernández M; Carrera D; Rosiñol L; Ribera JM; Ojanguren JM; Palomera L; Gardella S; Escoda L; Hernández-Boluda JC; Bello JL; de la Rubia J; Lahuerta JJ; San Miguel JF; GEM/PETHEMA Spanish Group.Leukemia. 2007 Jan;21(1):143-50. Epub 2006 Oct 5.
- Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Sancho JM; Ribera JM; Oriol A; Hernandez-Rivas JM; Rivas C; Bethencourt C; Parody R; Deben G; Bello JL; Feliu E; Programa para el Estudio y Tratamiento de Hemopatias Malignas Group. Cancer. 2006 Jun 15;106(12):2540-6.
© 2015 - IFMSA.org - Developed by web agency